MAUDE Adverse Event Report: ABBOTT VASCULAR XIENCE SIERRA EVEROLIMUS ELUTING CORONARY STENT SYSTEM; DRUG ELUTING CORONARY STENT DELIVERY SYSTEM

Model Number 1550300-28

Device Problem Adverse Event Without Identified Device or Use Problem (2993)

Patient Problems Cardiac Enzyme Elevation (1838); Low Blood Pressure/ Hypotension (1914); Pulmonary Edema (2020); Tachycardia (2095); Cardiogenic Shock (2262); Respiratory Failure (2484); Vascular Dissection (3160); Heart Failure/Congestive Heart Failure (4446)

Event Date 05/17/2021

Event Type  Death  

Manufacturer Narrative

The stent remains in the patient.Investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.The additional 3.0x23mm xience sierra referenced and the unk xience device referenced iare filed under separate medwatch report numbers.

Event Description

Patient id: (b)(6).It was reported that on (b)(6) 2021, a percutaneous coronary intervention (pci) was performed on the proximal left anterior descending (lad), left main (lm), and left circumflex (lcx) coronary arteries.Pre-dilatation was performed without complication.A 3.0x48mm abt ng des was unable to be delivered past the elbow due to anatomy.The abt ng des was successfully withdrawn.A guide-liner was placed and a non-flow limiting dissection of the lm was observed.An intra-aortic balloon pump (iabp) was placed, the patient was intubated and cardiovascular was consulted, recommending a stent to the lm.In replacement, a 2.5x23mm and a 3.0x23mm xience sierra stents were implanted in the proximal lad without a device issue reported.Reportedly, the second stent was observed mal-deployed post-implant.Post-deployment of the lad stents, a small dissection in the proximal cx was observed.As treatment for the dissection, a 3.0x28mm xience stent was placed from the lm to the proximal lcx.Post-deployment, a lm dissection was observed.As treatment, a 3.25x18mm xience stent was placed in the lm without an issue reported.As additional treatment, an unspecified xience stent delivery system (sds) attempted to cross, however, was unable to cross.During sds removal, the stent dislodged from the delivery system into the guide catheter.The patient had been intubated, medications were provided, and the patient was transferred to surgery for an emergent coronary artery bypass graft (cabg).Intravenous fluids/medication, blood/blood products and platelet transfusions were provided.Chest x-rays had been performed showing mild pulmonary edema.The patient had become tachycardic and hypotensive.Medications were provided.The patient had low cardiac output syndrome and had gone into cardiogenic shock with marked acidosis and elevated pro-b-type natriuretic peptide labs.Per echocardiogram, the patient was in severe post-operation left ventricular (lv) dysfunction.An impella had been placed via another percutaneous procedure.Elevated cardiac enzymes were observed without a myocardial infarction diagnosis reported.Medications and blood/blood product transfusions were provided.Following discussion with the physician, the family withdrew care.Medications and impella device were discontinued.On (b)(6) 2021, the patient expired due to cardiogenic shock and respiratory failure.Per physician, the events were unrelated to the 3.0x48mm abt ng des device that failed to cross.Per physician, the events were related to the procedure as cascading events from the dissection.No additional information was provided regarding this issue.

Manufacturer Narrative

The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.It should be noted that the reported patient effects of death, dissection, tachycardia, shock, respiratory failure, pulmonary edema, and hypotension are listed in the xience sierra, everolimus eluting coronary stent system instructions for use as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effect(s), and the relationship to the product, if any, cannot be determined; however, the reported treatment appears to be related to the operational context of the procedure.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling of the device.

• Brand Name: XIENCE SIERRA EVEROLIMUS ELUTING CORONARY STENT SYSTEM
• Type of Device: DRUG ELUTING CORONARY STENT DELIVERY SYSTEM
• Manufacturer (Section D): ABBOTT VASCULAR; 26531 ynez rd.; temecula CA 92591 4628
• MDR Report Key: 11958686
• MDR Text Key: 254873558
• Report Number: 2024168-2021-04758
• Device Sequence Number: 1
• Product Code: NIQ
• UDI-Device Identifier: 08717648227288
• UDI-Public: 08717648227288
• Combination Product (y/n): Y
• PMA/PMN Number: P110019
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: company representative,health
• Type of Report: Initial,Followup
• Report Date: 07/28/2021

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Expiration Date: 05/11/2022
• Device Model Number: 1550300-28
• Device Catalogue Number: 1550300-28
• Device Lot Number: 0110542
• Was Device Available for Evaluation?: No
• Initial Date Manufacturer Received: 05/17/2021
• Initial Date FDA Received: 06/08/2021
• Supplement Dates Manufacturer Received: 07/14/2021
• Supplement Dates FDA Received: 07/28/2021
• Is This a Reprocessed and Reused Single-Use Device?: No
• Patient Sequence Number: 1
• Treatment: TWO XIENCE SIERRA STENTS.; TWO XIENCE SIERRA STENTS
• Patient Outcome(s): Death
• Patient Age: 69 YR
• Patient Weight: 60